Nuclear medicine uses radioactive molecules, so-called radiopharmaceuticals, and their radiation to provide diagnostic information and treat various medical conditions such as cancer. The radioactive elements, known as radionuclides, possess excess energy that is released by different types of radioactive decay. The key objective of the EU-funded PRISMAP project is to establish a European infrastructure and a common entry point for researchers and physicians in the field. The consortium will set up a sustainable source of highly pure non-conventional radionuclides for developments in medicine as well as protocols and services for the pharmaceutical industry and the healthcare sector, in a sustainable European medical radionuclide programme.
- More info on the project: https://www.prismap.eu/
- More info on the access: https://www.prismap.eu/access/